Biotech earnings were mixed midweek, but sector indices held up despite a few sagging stocks.

Onyx ( ONXX) shares closed down $1.48, or 3.7%, at $38.36 on Wednesday. The company reported its quarterly results Tuedsay after the close, beating on EPS by a penny and surpassing revenue expectations. However, Wall Street viewed the company's new Nexavar sales guidance as underwhelming. The company guided to sales of $660 million to $675 million, up from $600 million to $650 million. Wall Street analysts had expected anywhere from between $650 and $700 million.

Meanwhile, BioMarin ( BMRN) gave up $1.60, or 5.0%, to $30.10 and analysts dropped their price targets for the stock a day after it presented second quarter results. BioMarin's phenylketonuria (PKU) drug Kuvan registered $12 million in second-quarter sales, falling short of the $14.8 million consensus. And BioMarin scaled back the top end of its guidance for Kuva revenue by $5 million to $65 million.

On the postive side, sales of its Naglazyme rose 68% to $35.1 million, surpassing expectations for $29.7 million, and the company boosted overall revenue expectations for 2008.

Another stock in the red on midweek, Medarex ( MEDX) reported a widened quarterly loss and revenue below targets. The company reported a loss of $53.1 million, or 42 cents a share, vs. a loss of 32 cents a share a year prior. Factoring out one time charges, the company said it lost 34 cents a share for the quarter. Analysts polled by Thomson Financial expected a loss of 35 cents per share on revenue of $12.5 million.

Its shares gave up 92 cents a share, or 9.3%, to $9.02 on Wednesday.

Onyx, BioMarin and Medarex are all components of the Nasdaq biotechnology index, but gains elsewhere kept it up by 3.25, or 0.4%, at 919.13.

One component faring better, Albany Molecular Research Inc (AMRI) ( AMRI) shares rose $2.66, or 17.6%, at $17.77. The company reported net income of 18 cents a share, or 24 cents a share factoring out a restructuring charge, on revenue that increased 17% to $57.9 million. Contract revenue for the discovery services segment and development/small scale manufacturing segment climbed 54% and 43%, respectively.

Looking ahead, AMRI sees contract revenue of between $186 and $190 million for 2008 and upped its guidance to between 48 cents and 52 cents a share, from between 38 cents and 42 cents a share.

Another stock in the green, clinical research organization Kendle ( KNDL) beat second quarter targets and then upped its 2008 profit guidance to between $2 and $2.15 a share from between $1.90 and $2.07 a share. The company also increased its expectations for service revenue by $40 million to a range of $490 and $500 million a share. Its shares traded up $4.76, or 11.72%, to $45.36.

In analyst actions, Canaccord Adams downgraded biotechnology company Exelixis ( EXEL) to hold from buy. Also, Lazard lowered its price target for the stock to $10 from $12.

Exelixis shares traded $1.14, or 16.0% lower, at $5.97 the first trading day after its quarterly earnings release.

More from Investing

Alibaba Reports Earnings on Thursday: 5 Key Things to Watch

Alibaba Reports Earnings on Thursday: 5 Key Things to Watch

Amazon Is Not Killing Every Retailer, Only These Laggards

Amazon Is Not Killing Every Retailer, Only These Laggards

Wall Street Still Thinks Tesla Could Soar to Elon Musk's $420 Target Price

Wall Street Still Thinks Tesla Could Soar to Elon Musk's $420 Target Price

Investors May Have Omarosa to Thank for Pretty Good Week

Investors May Have Omarosa to Thank for Pretty Good Week

Investing For Retirement: What Not to Worry About

Investing For Retirement: What Not to Worry About